The Effect of Anti-rheumatic Drugs on the Skeleton

Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K (2000) The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 39:122–132

CAS  Article  Google Scholar 

Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo county rheumatoid arthritis register. Arthritis Rheum 43:522–530

CAS  PubMed  Article  Google Scholar 

Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Reduced bone mineral density in male rheumatoid arthritis patients—frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo county rheumatoid arthritis register. Arthritis Rheum 43:2776–2784

CAS  PubMed  Article  Google Scholar 

Hauser B, Riches PL, Wilson JF, Horne AE, Ralston SH (2014) Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) 53:1759–1766

CAS  Article  Google Scholar 

van Staa TP, Geusens P, Bijlsma JWJ, Leufkens HGM, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112

PubMed  Article  Google Scholar 

Xue AL, Wu SY, Jiang L, Feng AM, Guo HF, Zhao P (2017) Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore) 96:e6983

Article  Google Scholar 

Shim JH, Stavre Z, Gravallese EM (2018) Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications. Calcif Tissue Int 102:533–546

CAS  PubMed  Article  Google Scholar 

Schett G, Saag KG, Bijlsma JWJ (2010) From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 69:1415–1419

CAS  PubMed  Article  Google Scholar 

McInnes IB, Schett G (2011) Mechanisms of disease the pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219

CAS  PubMed  Article  Google Scholar 

Hauser B, Harre U (2018) The role of autoantibodies in bone metabolism and bone loss. Calcif Tissue Int 102:522–532

CAS  PubMed  Article  Google Scholar 

Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Jakobsson PJ, Baum W, Nimmerjahn F, Szarka E, Sarmay G, Krumbholz G, Neumann E, Toes R, Scherer HU, Catrina AI, Klareskog L, Jurdic P, Schett G (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Investig 122:1791–1802

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hauser B, Riches PL, Gilchrist T, Visconti MR, Wilson JF, Ralston SH (2015) Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Ann Rheum Dis 74:1631–1632

CAS  PubMed  Article  Google Scholar 

Tsukasaki M, Takayanagi H (2019) Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol 19:626–642

CAS  PubMed  Article  Google Scholar 

Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Muller-Ladner U, Mysler EF, da Silva JAP, Poor G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685–699

CAS  PubMed  Article  Google Scholar 

Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva JA, Griep EN, Klaasen R, Allaart CF, Baudoin P, Raterman HG, Szekanecz Z, Buttgereit F, Masaryk P, Klausch LT, Paolino S, Schilder AM, Lems WF, Cutolo M, For the GLORIA Trial consortium (2022) Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis 81(7):925–936

Article  Google Scholar 

Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16:145–154

CAS  PubMed  Article  Google Scholar 

Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511–520

PubMed  Article  Google Scholar 

Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, Gough A, Quinn M, Reece R, Cox SR, Buch MH, van der Heijde DM, Emery P (2014) A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis 73:1027–1036

CAS  PubMed  Article  Google Scholar 

den Uyl D, ter Wee M, Boers M, Kerstens P, Voskuyl A, Nurmohamed M, Raterman H, van Schaardenburg D, van Dillen N, Dijkmans B, Lems W (2014) A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 73:1071–1078

Google Scholar 

Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR, Smith CD (2001) The effect of low dose methotrexate on bone density. J Rheumatol 28:2395–2399

CAS  PubMed  Google Scholar 

Tascioglu F, Oner C, Armagan O (2003) The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis. Rheumatol Int 23:231–235

CAS  PubMed  Article  Google Scholar 

Rolvien T, Jandl NM, Sturznickel J, Beil FT, Kotter I, Oheim R, Lohse AW, Barvencik F, Amling M (2021) Clinical and radiological characterization of patients with immobilizing and progressive stress fractures in methotrexate osteopathy. Calcif Tissue Int 108:219–230

CAS  PubMed  Article  Google Scholar 

Robin F, Cadiou S, Albert JD, Bart G, Coiffier G, Guggenbuhl P (2021) Methotrexate osteopathy: five cases and systematic literature review. Osteoporos Int 32:225–232

CAS  PubMed  Article  Google Scholar 

Ragab AH, Frech RS, Vietti TJ (1970) Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 25:580–585

CAS  PubMed  Article  Google Scholar 

Ruffer N, Krusche M, Beil FT, Amling M, Kotter I, Rolvien T (2022) Clinical features of methotrexate osteopathy in rheumatic musculoskeletal disease: a systematic review. Semin Arthritis Rheum 52:151952

CAS  PubMed  Article  Google Scholar 

May KP, West SG, McDermott MT, Huffer WE (1994) The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 37:201–206

CAS  PubMed  Article  Google Scholar 

Carbone L, Vasan S, Elam R, Gupta S, Tolaymat O, Crandall C, Wactawski-Wende J, Johnson KC (2020) The association of methotrexate, sulfasalazine, and hydroxychloroquine use with fracture in postmenopausal women with rheumatoid arthritis: findings from the women’s health initiative. JBMR Plus 4:e10393

CAS  PubMed  PubMed Central  Article  Google Scholar 

Elkayam O, Paran D, Flusser G, Wigler I, Yaron M, Caspi D (2000) Insufficiency fractures in rheumatic patients: misdiagnosis and underlying characteristics. Clin Exp Rheumatol 18:369–374

CAS  PubMed  Google Scholar 

Buehring B, Al-Azem N, Andreica I, Kiefer D, Kiltz U, Tsiami S, Baraliakos X, Braun J (2021) Prevalence and risk factors of insufficiency fractures of the foot and ankle joint in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 73:2378–2380

Google Scholar 

Tengstrand B, Hafstrom I (2002) Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol 29:2299–2305

CAS  PubMed  Google Scholar 

Jin C, Zhang P, Zhang M, Zhang X, Lv L, Liu H, Liu Y, Zhou Y (2017) Inhibition of SLC7A11 by sulfasalazine enhances osteogenic differentiation of mesenchymal stem cells by modulating BMP2/4 expression and suppresses bone loss in ovariectomized mice. J Bone Miner Res 32:508–521

CAS  PubMed  Article  Google Scholar 

de Steenwinkel F, Hokken-Koelega A, Hazes J, Dolhain RJ (2013) Does elevated disease activity or medication use influence the bone density of the prepubertal offspring in pregnant women with rheumatoid arthritis? Arthritis and rheumatism. Wiley-Blackwell, HOBOKEN, pp S172–S172

Google Scholar 

Both T, Zillikens MC, Hoorn EJ, Zietse R, van Laar JA, Dalm VA, van Duijn CM, Versnel MA, Maria NI, van Hagen PM, van Daele PL (2016) Bone mineral density in sjogren syndrome patients with and without distal renal tubular acidosis. Calcif Tissue Int 98:573–579

CAS  PubMed  PubMed Central  Article  Google Scholar 

Both T, Zillikens MC, Schreuders-Koedam M, Vis M, Lam WK, Weel A, van Leeuwen J, van Hagen PM, van der Eerden BCJ, van Daele PLA (2018) Hydroxychloroquine affects bone resorption both in vitro and in vivo. J Cell Physiol 233:1424–1433

CAS  PubMed  Article  Google Scholar 

Both T, van de Peppel HJ, Zillikens MC, Koedam M, van Leeuwen J, van Hagen PM, van Daele PLA, van der Eerden BCJ (2018) Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. J Cell Mol Med 22:873–882

CAS  PubMed  Google Scholar 

McInnes IB, Gravallese EM (2021) Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol 21:680–686

CAS  PubMed  PubMed Central  Article  Google Scholar 

Herman S, Muller RB, Kronke G, Zwerina J, Redlich K, Hueber AJ, Gelse H, Neumann E, Muller-Ladner U, Schett G (2008) Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum 58:3041–3050

CAS  PubMed  Article 

留言 (0)

沒有登入
gif